
消化器内科学教室

2024 年 英語原著論文

1. Tanaka H, Oka S, Shiotani A, Sugimoto M, Suzuki H, Naito Y, Handa O, Hisamatsu T, Fukudo S, Fujishiro M, Motoya S, Yahagi N, Yamaguchi S, Chan FKL, Lee SY, Li B, Ang TL, Abdullah M, Tablante MC, Prachayakul V, Tanaka S: International Gastrointestinal Consensus Symposium Study Group. Current Status of Diagnosis and Treatment of Colorectal Cancer in Asian Countries: A Questionnaire Survey. *Digestion*. 2024;105(1):62-68. doi: 10.1159/000531706.
2. Morikubo H, Tojima R, Maeda T, Matsuoka K, Matsuura M, Miyoshi J, Tamura S, Hisamatsu T: Machine learning using clinical data at baseline predicts the medium-term efficacy of ustekinumab in patients with ulcerative colitis. *Sci Rep*. 2024 Feb 22;14(1):4386. doi: 10.1038/s41598-024-55126-1.
3. Danese S, Panaccione R, Feagan BG, Afzali A, Rubin DT, Sands BE, Reinisch W, Panés J, Sahoo A, Terry NA, Chan D, Han C, Frustaci ME, Yang Z, Sandborn WJ, Hisamatsu T, Andrews JM, D'Haens GR; GALAXI-1 Study Group: Efficacy and safety of 48 weeks of guselkumab for patients with Crohn's disease: maintenance results from the phase 2, randomised, double-blind GALAXI-1 trial. *Lancet Gastroenterol Hepatol*. 2024 Feb;9(2):133-146. doi: 10.1016/S2468-1253(23)00318-7.
4. Khalaf K, Seleq S, Bourke MJ, Alkandari A, Bapaye A, Bechara R, Calo NC, Fedorov ED, Hassan C, Kalauz M, Kandel GP, Matsuda T, May GR, Mönkemüller K, Mosko JD, Ohno A, Pavic T, Pellisé M, Raos Z, Repici A, Rex DK, Saxena P, Schauer C, Sethi A, Sharma P, Shaukat A, Siddiqui UD, Singh R, Smith LA, Tanabe M, Teshima CW, von Renteln D, Gimpaya N, Pawlak KM, Angeli Fujiyoshi MR, Fujiyoshi Y, Lamba M, Li S, Malipatil SB, Grover SC: Establishment of standards for the referral of large nonpedunculated colorectal polyps: an international expert consensus using a modified Delphi process. *Gastrointest Endosc*. 2024 Sep;100(3):510-516.e6. doi: 10.1016/j.gie.2024.02.001.
5. Sands BE, D'Haens G, Clemow DB, Irving PM, Johns JT, Hunter Gible T,

- Abreu MT, Lee S, Hisamatsu T, Kobayashi T, Dubinsky MC, Vermeire S, Siegel CA, Peyrin-Biroulet L, Moses RE, Milata J, Arora V, Panaccione R, Dignass A: Two-Year Efficacy and Safety of Mirikizumab Following 104 Weeks of Continuous Treatment for Ulcerative Colitis: Results From the LUCENT-3 Open-Label Extension Study. *Inflamm Bowel Dis*. 2024 Dec 5;30(12):2245-2258. doi: 10.1093/ibd/izae024. Erratum in: *Inflamm Bowel Dis*. 2024 Jun 3;30(6):1044-1045. doi: 10.1093/ibd/izae096.
6. Komatsu H, Morikubo H, Kimura Y, Moue C, Yonezawa H, Matsuura M, Miyoshi J, Hisamatsu T: A combination of bowel wall thickness and submucosa index is useful for estimating endoscopic improvement in ulcerative colitis: external validation of the Kyorin Ultrasound Criterion. *J Gastroenterol*. 2024 Mar;59(3):209-215. doi: 10.1007/s00535-024-02077-z.
 7. Naganuma M, Nakamura N, Kunisaki R, Matsuoka K, Yamamoto S, Kawamoto A, Saito D, Kobayashi T, Nanki K, Narimatsu K, Shiga H, Esaki M, Yoshioka S, Kato S, Saruta M, Tanaka S, Yasutomi E, Yokoyama K, Moriya K, Tsuzuki Y, Ooi M, Fujiya M, Nakazawa A, Takagi T, Omori T, Tahara T, Hisamatsu T: Japanese UC Study Group. Medical treatment selection and outcomes for hospitalized patients with severe ulcerative colitis as defined by the Japanese criteria. *J Gastroenterol*. 2024 Apr;59(4):302-314. doi: 10.1007/s00535-024-02079-x.
 8. Horanai C, Hashimoto H, Hisamatsu T, Ikeuchi H, Watanabe K, Nanjo S, Nezu R, Itabashi M, Hokari R, Higashi D, Matsuura M, Ogino T, Takahashi K, Andoh A, Shinozaki M, Sugita A: Association Between Sense of Coherence, Disease-Specific Symptoms, and Health-Related Quality of Life Among Japanese Patients with Ulcerative Colitis: A Cross-Sectional Study. *Digestion*. 2024;105(4):257-265. doi: 10.1159/000538618.
 9. Kimura Y, Miyoshi J, Morikubo H, Komatsu H, Moue C, Yonezawa H, Matsuura M, Hisamatsu T: Early sonographic improvement predicts clinical remission and mucosal healing with molecular-targeted drugs in ulcerative colitis. *Gastro Hep Advances* 2024 Apr 23;3(6):703-710. doi: 10.1016/j.gastha.2024.04.007.
 10. Nemoto N, Inami T, Onozawa S, Kohno T, Nagahama K, Soejima K, Hisamatsu T: A case report of limitation of transcatheter hepatic arterial embolization for hereditary hemorrhagic telangiectasia type 2 with pulmonary arterial hypertension. *Int J Surg Case Rep*. 2024 Apr 19;119:109634. doi:

10.1016/j.ijscr.2024.109634.

11. Afif W, Arasaradnam RP, Abreu MT, Danese S, Sandborn WJ, Miao Y, Zhang H, Panaccione R, Hisamatsu T, Scherl EJ, Leong RW, Rowbotham DS, Peyrin-Biroulet L, Sands BE, Marano C: Efficacy and Safety of Ustekinumab for Ulcerative Colitis Through 4 Years: Final Results of the UNIFI Long-Term Maintenance Study. *Am J Gastroenterol*. 2024 May 1;119(5):910-921. doi: 10.14309/ajg.0000000000002621.
12. Shibayama T, Hayashi A, Toki M, Kitahama K, Ho YJ, Kato K, Yamada T, Kawamoto S, Kambayashi K, Ochiai K, Gondo K, Okano N, Melchor JP, Iacobuzio-Donahue CA, Sakamoto Y, Hisamatsu T, Shibahara J: Combination immunohistochemistry for CK5/6, p63, GATA6, and HNF4a predicts clinical outcome in treatment-naïve pancreatic ductal adenocarcinoma. *Sci Rep*. 2024 Jul 6;14(1):15598. doi: 10.1038/s41598-024-65900-w.
13. Ohno A, Miyamoto N, Kaji R, Shirakawa T, Watanabe M, Sumi R, Jinbo Y, Kusuhashi M, Miyoshi J, Hisamatsu T: The influence of color vision deficiency on vessel visibility during colorectal endoscopic submucosal dissection and the potential advantage of red dichromatic imaging to achieve color vision barrier-free. *DEN Open*. 2024 Jul 19;5(1):e410. doi: 10.1002/deo2.410.
14. Colombel JF, Hisamatsu T, Atreya R, Bresso F, Thin L, Panaccione R, Parra RS, Ford S, Remple VP, Lacerda AP, Anyanwu SI, Mallick M, Garrison A, Regueiro M: Upadacitinib Reduces Crohn's Disease Symptoms Within the First Week of Induction Therapy. *Clin Gastroenterol Hepatol*. 2024 Aug;22(8):1668-1677. doi: 10.1016/j.cgh.2024.02.027.
15. Louis E, Schreiber S, Panaccione R, Bossuyt P, Biedermann L, Colombel JF, Parkes G, Peyrin-Biroulet L, D'Haens G, Hisamatsu T, Siegmund B, Wu K, Boland BS, Melmed GY, Armuzzi A, Levine P, Kalabic J, Chen S, Cheng L, Shu L, Duan WR, Pivorunas V, Sanchez Gonzalez Y, D'Cunha R, Neimark E, Wallace K, Atreya R, Ferrante M, Loftus EV Jr; INSPIRE and COMMAND Study Group: Risankizumab for Ulcerative Colitis: Two Randomized Clinical Trials. *JAMA*. 2024 Sep 17;332(11):881-897. doi: 10.1001/jama.2024.12414.
16. Oguri N, Miyoshi J, Nishinarita Y, Wada H, Nemoto N, Hibi N, Kawamura N, Miyoshi S, Lee STM, Matsuura M, Osaki T, Hisamatsu T: Akkermansia muciniphila in the small intestine improves liver fibrosis in a murine liver

cirrhosis model. *NPJ Biofilms Microbiomes*. 2024 Sep 16;10(1):81. doi: 10.1038/s41522-024-00564-y.

17. Takeuchi K, Hisamatsu T, Nakase H, Matsuoka K, Keating M, Yuasa H, Oe M, Arai S, Mazur R, Hibi T: Efficacy and safety of etrasimod in patients with ulcerative colitis in Japan: data from the phase 3 ELEVATE UC 12 and ELEVATE UC 40 JAPAN trials. *Digestion*. 2024 Sep 24:1-9. doi: 10.1159/000541383.
18. Khalaf K, Seleq S, Bourke MJ, Alkandari A, Bapaye A, Bechara R, Calo NC, Fedorov ED, Hassan C, Kalauz M, Kandel GP, Matsuda T, May GR, Mönkemüller K, Mosko JD, Ohno A, Pavic T, Pellisé M, Raos Z, Repici A, Rex DK, Saxena P, Schauer C, Sethi A, Sharma P, Shaukat A, Siddiqui UD, Singh R, Smith LA, Tanabe M, Teshima CW, von Renteln D, Gimpaya N, Pawlak KM, Angeli Fujiyoshi MR, Fujiyoshi Y, Lamba M, Li S, Malipatil SB, Grover SC. Establishment of standards for the referral of large nonpedunculated colorectal polyps: an international expert consensus using a modified Delphi process. *Gastrointest Endosc*. 2024 Sep;100(3):510-516.e6. doi: 10.1016/j.gie.2024.02.001.
19. Sands BE, D'Haens G, Clemow DB, Irving PM, Johns JT, Gobble TH, Abreu MT, Lee SD, Hisamatsu T, Kobayashi T, Dubinsky MC, Vermeire S, Siegel CA, Peyrin-Biroulet L, Moses RE, Milata J, Panaccione R, Dignass A: Three-Year Efficacy and Safety of Mirikizumab Following 152 Weeks of Continuous Treatment for Ulcerative Colitis: Results From the LUCENT-3 Open-Label Extension Study. *Inflamm Bowel Dis*. 2024 Oct 25:izae253. doi: 10.1093/ibd/izae253.
20. Schreiber S, Feagan BG, Louis E, Hisamatsu T, Hibi T, Dron L, Jamoul C, Patel H, Harris K, Taliadouros V, Oortwijn A, Peyrin-Biroulet L: Distinct trajectories of symptomatic response in ulcerative colitis during filgotinib therapy: A post hoc analysis from the SELECTION study. *United European Gastroenterol J*. 2024 Nov;12(9):1243-1255. doi: 10.1002/ueg2.12686.
21. Atreya R, Ferrante M, Panaccione R, Feagan B, Shchukina O, Jairath V, Rieder F, Hisamatsu T, Siegmund B, Kligys K, Song A, Zambrano J, Mallick M, Zhang Y, Armuzzi A, D'Haens G: Risankizumab Is Associated With Normalization of Biomarkers in Patients With Crohn's Disease: Results From the Phase 3 ADVANCE, MOTIVATE, and FORTIFY Studies. *J Crohns Colitis*. 2024 Nov 1:jjae164. doi: 10.1093/ecco-jcc/jjae164.

22. Hibi T, Hirohata S, Hisamatsu T, Kikuchi H, Takeno M, Sato N, Mizuno N, Tashiro M, Susuta Y, Ishigatsubo Y: Real-World Safety and Effectiveness of Infliximab in 255 Patients with Intestinal, Neurological, and Vascular Behçet's Disease: A Post-Marketing Surveillance. *Adv Ther.* 2024 Dec;41(12):4476-4497. doi: 10.1007/s12325-024-02993-9.
23. Sands BE, D'Haens G, Clemow DB, Irving PM, Johns JT, Gobble TH, Abreu MT, Lee SD, Hisamatsu T, Kobayashi T, Dubinsky MC, Vermeire S, Siegel CA, Peyrin-Biroulet L, Moses RE, Milata J, Panaccione R, Dignass A: Two-Year Efficacy and Safety of Mirikizumab Following 104 Weeks of Continuous Treatment for Ulcerative Colitis: Results From the LUCENT-3 Open-Label Extension Study. *Inflamm Bowel Dis.* 2024 Dec 5;30(12):2245-2258. doi: 10.1093/ibd/izae024.
24. Nakase H, Wagatsuma K, Kobayashi T, Matsumoto T, Esaki M, Watanabe K, Kunisaki R, Takeda T, Arai K, Ibuka T, Ishikawa D, Matsuno Y, Sakuraba H, Ueno N, Yokoyama K, Saruta M, Hokari R, Yokoyama J, Tamano S, Nojima M, Hisamatsu T: MEFV-IBDU Group. Involvement of Mediterranean fever gene mutations in colchicine-responsive enterocolitis: a retrospective cohort study. *EBioMedicine.* 2024 Dec;110:105454. doi: 10.1016/j.ebiom.2024.105454.
25. Ferrante M, D'Haens G, Jairath V, Danese S, Chen M, Ghosh S, Hisamatsu T, Kierkus J, Siegmund B, Bragg SM, Crandall W, Durand F, Hon E, Lin Z, Lopes MU, Morris N, Protic M, Carlier H, Sands BE: VIVID Study Group. Efficacy and safety of mirikizumab in patients with moderately-to-severely active Crohn's disease: a phase 3, multicentre, randomised, double-blind, placebo-controlled and active-controlled, treat-through study. *Lancet.* 2024 Dec 14;404(10470):2423-2436. doi: 10.1016/S0140-6736(24)01762-8.
26. Takenaka K, Hisamatsu T, Kobayashi T, Yamamoto H, Ohmiya N, Hayashi R, Matsuoka K, Saruta M, Andoh A, Fukata N, Watanabe K, Imaeda H, Hirai F, Matsumoto T, Hirakawa A, Yano T, Matsuura M, Okamoto R, Ohtsuka K, Watanabe M: Inadequate Efficacy of Biologics for Treating Proximal Ileal Lesions in Crohn's Disease; a prospective multicenter study. *Clin Gastroenterol Hepatol.* 2024 Dec 16:S1542-3565(24)01084-X. doi: 10.1016/j.cgh.2024.10.030.
27. Naganuma M, Takeno M, Çelik AF, Moots R, Pinton P, Hisamatsu T: Assessment of IL-6 Pathway Inhibition in Gastrointestinal Behçet's Disease from Immunological and Clinical Perspectives. *Biomedicines.* 2025 Jan 20;13(1):247.

doi: 10.3390/biomedicines13010247.

28. Okabe M, Yamamoto S, Shiokawa M, Hisamatsu T, Yamazaki H, Nakanishi R, Hamada K, Kitamoto H, Kuwada T, Uza N, Sakatani A, Fujii T, Ohno M, Matsuura M, Shibuya T, Ohmiya N, Ooi M, Hoshi N, Moriya K, Tsuchiya K, Yamaguchi Y, Kunisaki R, Takahara M, Takagi T, Takehara T, Hirai F, Kakimoto K, Esaki M, Nakase H, Kinjo F, Torisu T, Kanmura S, Narimatsu K, Matsuoka K, Hiraga H, Yokoyama K, Honzawa Y, Naganuma M, Saruta M, Kodama Y, Chiba T, Seno H: Anti-integrin α v β 6 antibody as a biomarker for diagnosing ulcerative colitis: a nationwide multicenter validation study. *J Gastroenterol.* 2025 Jan;60(1):86-95. doi: 10.1007/s00535-024-02176-x.
29. Rubin DT, Allegretti JR, Panés J, Shipitofsky N, Yarandi SS, Huang KG, Germinaro M, Wilson R, Zhang H, Johanns J, Feagan BG, Hisamatsu T, Lichtenstein GR, Bressler B, Peyrin-Biroulet L, Sands BE, Dignass A: QUASAR Study Group. Guselkumab in patients with moderately to severely active ulcerative colitis (QUASAR): phase 3 double-blind, randomised, placebo-controlled induction and maintenance studies. *Lancet.* 2025 Jan 4;405(10472):33-49. doi: 10.1016/S0140-6736(24)01927-5.
30. Kobayashi T, Hisamatsu T, Motoya S, Fujii T, Kunisaki R, Shibuya T, Matsuura M, Takeuchi K, Hiraoka S, Yasuda H, Yokoyama K, Takatsu N, Maemoto A, Tahara T, Tominaga K, Shimada M, Kuno N, Fernandez JL, Ishiguro K, Cavaliere M, Deguchi H, Hibi T: Factors affecting 1-year persistence with vedolizumab for ulcerative colitis: a multicenter, retrospective real-world study. *Intest Res.* 2025 Jan 16. doi: 10.5217/ir.2024.00063.
31. Komatsu H, Morikubo H, Kimura Y, Moue C, Yonezawa H, Matsuura M, Miyoshi J, Hisamatsu T: Determination of optimal cutoff value of ulcerative colitis intestinal ultrasound index to estimate endoscopic improvement in ulcerative colitis. *J Gastroenterol.* 2025 Feb;60(2):166-173. doi: 10.1007/s00535-024-02172-1.
32. Miyoshi J, Hisamatsu T: Effect of maternal exposure to antibiotics during pregnancy on the neonatal intestinal microbiome and health. *Clin J Gastroenterol.* 2025 Feb;18(1):1-10. doi: 10.1007/s12328-024-02088-6.
33. Panaccione R, Ferrante M, Dotan I, Panés J, Hisamatsu T, Bossuyt P, Danese S, Song A, Kalabic J, Joshi N, Zambrano J, Zhang Y, Duan WR, Kligys K, Dubinsky

MC, Lindsay JO, Vermeire S, Siegmund B, Irving PM, D'Haens G: Extended Risankizumab Treatment in Patients With Crohn's Disease Who Did Not Achieve Clinical Response to Induction Treatment. *Clin Gastroenterol Hepatol*. 2025 Feb 3:S1542-3565(25)00082-5. doi: 10.1016/j.cgh.2024.12.023.

34. Miyoshi J, Yoon A, Matsuura M, Hisamatsu T. Real-world use of biologics during the first year of treatment for newly diagnosed Crohn's disease in Japan: a claims analysis from 2010 to 2021. *Intest Res*. 2025 Jan 23. doi: 10.5217/ir.2024.00082.
35. Tsuzuki Y, Shiotani A, Miyaguchi K, Ono S, Saito Y, Sugimoto M, Naito Y, Nomura S, Handa O, Hisamatsu T, Fujishiro M, Matsuda T, Morita Y, Yahagi N, Chan FKL, Ang TL, Abdullah M, Tablante MC, Prachayakul V, Li B, Jung HY, Matsumoto H, Shiomi R, Imaeda H: Questionnaire Survey on the Diagnosis and Treatments of Eosinophilic Gastrointestinal Diseases (EGID) in Asia. *Digestion*. 2025 Feb 13:1-14. doi: 10.1159/000544725.
36. Hibi T, Kobayashi T, Tanaka M, Osaga S, Potts Bleakman AJ, Hunter Gible T, Nedeljkovic Protic M, Redondo I, Matsuo K, Hisamatsu T: Patient and Health Care Professional Perspectives on the Burden and Daily Life Impact of Ulcerative Colitis and Crohn's Disease: Results from the Japanese CONFIDE Study. *Adv Ther*. 2025 Feb 28. doi: 10.1007/s12325-024-03078-3.
37. Hisamatsu T, Naganuma M, Pinton P, Takeno M: Behçet's disease: incidence, prevalence, and real-word data on the use of biologic agents in Japan. *J Gastroenterol*. 2025 Mar;60(3):294-305. doi: 10.1007/s00535-024-02191-y.
38. Matsumoto T, Hisamatsu T, Esaki M, Omori T, Sakuraba H, Shinzaki S, Sugimoto K, Takenaka K, Naganuma M, Bamba S, Hisabe T, Hiraoka S, Fujiya M, Matsuura M, Yanai S, Watanabe K, Ogata H, Andoh A, Nakase H, Ohtsuka K, Hirai F, Fujishiro M, Igarashi Y, Tanaka S: Guidelines for endoscopic diagnosis and treatment of inflammatory bowel diseases. *Dig Endosc*. 2025 Mar 3. doi: 10.1111/den.15002.
39. Ogino Y, Sadashima K, Yoshida Y, Takedomi H, Tsuruoka N, Sakata Y, Takamori A, Hisamatsu T, Matsumoto T, Esaki M: Development of a capsule endoscopy scoring system for the early diagnosis of small bowel Crohn's disease. *J Gastroenterol*. 2025 Mar 7. doi: 10.1007/s00535-025-02235-x.

40. Hart A, Panaccione R, Steinwurz F, Danese S, Hisamatsu T, Cao Q, Ritter T, Seidler U, Olurinde M, Vetter ML, Yee J, Yang Z, Wang Y, Johanns J, Han C, Sahoo A, Terry NA, Sands BE, D'Haens G. Efficacy and Safety of Guselkumab Subcutaneous Induction and Maintenance in Participants with Moderately to Severely Active Crohn's Disease: Results from the Phase 3 GRAVITI Study. *Gastroenterology*. 2025 Mar 18:S0016-5085(25)00522-0. doi: 10.1053/j.gastro.2025.02.033.